What is the half-life of a peptide?

A peptide's half-life is the time it takes for the amount in the bloodstream to fall to half of its starting level. It is a measure of how quickly the body removes the molecule. Half-lives range from a few minutes for fragile natural peptides to several days for peptides that have been chemically engineered to resist enzyme breakdown, so there is no single answer that fits every peptide.

Which peptides have the longest half-life?

The engineered GLP-1 receptor agonists are the standout long-acting group. Semaglutide and tirzepatide both carry reported half-lives of around five days, which is what allows their approved prescription forms to be taken once weekly. These long half-lives come from structural modifications, such as a fatty-acid chain that binds to albumin, that slow the molecule's clearance far below that of a natural hormone.

How long do peptides stay in your system?

It depends entirely on the peptide. As a rough guide, short-acting peptides leave the bloodstream within minutes to a couple of hours, medium-acting ones persist for several hours, and long-acting ones can last a day or more. A common rule of thumb is that a molecule is largely gone after about four to five half-lives. For many research-grade peptides, though, the human pharmacokinetics have never been formally measured, so published figures are estimates.

Does a longer half-life mean a peptide is better?

No. Half-life describes only how long a molecule persists in the body, not whether it is effective or safe. A long half-life can be convenient for how a medicine is designed, but it is a chemical property, not a benefit. Reading a chart correctly means treating half-life as one descriptive number among many, and keeping in mind that research-grade peptides are generally not FDA-approved and that human evidence for many of them is limited.

Peptide Half-Life Chart: How Long Peptides Stay in Your System

By MrPepTalks Editorial · Updated 2026-07-08

One of the first things people notice when they compare peptides side by side is that they do not all behave the same way in time. Some are gone from the bloodstream in minutes; others linger for days. That single number, the half-life, quietly explains a huge amount about a peptide, from how researchers design a study around it to why two molecules aimed at the same target can feel completely different. This guide is a plain-English peptide half-life chart and an explainer of what that number actually means. It is framed as pharmacokinetics, the science of how a molecule is absorbed, distributed and removed from the body, not as usage or timing guidance. Nothing here is a protocol, and it should not be read as medical advice.

What half-life actually means

A peptide's half-life is the time it takes for the amount in the bloodstream to fall to half of its starting level. If a molecule has a half-life of one hour, then after one hour roughly half remains, after two hours a quarter, and so on, decreasing along a predictable curve. It is a property of the molecule and the body's clearance machinery, not a schedule anyone chooses. Half-life is one of the core numbers pharmacologists report because it captures how quickly the body dismantles and removes a compound. A short half-life means rapid clearance; a long half-life means the molecule persists. When you read that a peptide is 'long-acting' or 'short-acting', half-life is usually the number underneath that description. For more on how to interpret figures like this from a study, see our guide on how to read a peptide study.

Why peptide half-lives vary so much

The body breaks peptides down the way it breaks down food. Enzymes called peptidases are everywhere in blood and tissue, and their job is to snip amino-acid chains apart, so an unmodified natural peptide is often degraded within minutes. This is why many native signaling peptides have extremely short half-lives. Drug developers spend enormous effort fighting that clearance. They modify a sequence to resist enzymes, attach it to a fatty-acid chain so it binds to albumin and rides along in the blood, or otherwise slow down how fast the kidneys and enzymes remove it. Semaglutide is a well-known example of this engineering: structural changes give it a half-life measured in days rather than the minutes a natural GLP-1 hormone would have. So a peptide's half-life reflects both its intrinsic chemistry and how much it has been deliberately altered to survive longer. Size, charge, and whether it is given by injection or another route all feed into the final number.

Peptide half-life chart: short, medium and long-acting groups

It helps to think in three broad bands rather than memorizing exact figures, because reported half-lives vary between sources and are often estimated. Very short-acting peptides leave the bloodstream within minutes to a couple of hours; many growth-hormone-releasing peptides and natural signaling fragments sit here. Medium-acting peptides persist for several hours. Long-acting peptides last a day or more, and the GLP-1 weight-management molecules are the standout example, with half-lives long enough to be measured in days. As a rough orientation: natural GLP-1 disappears within minutes, while the engineered GLP-1 receptor agonists semaglutide and tirzepatide both carry reported half-lives of around five days, and several research peptides such as BPC-157 have short and, importantly, not-well-established human half-lives. The key honest caveat is that for many research-grade peptides the human pharmacokinetics have simply never been formally measured, so any single number is an estimate at best.

Worked examples from widely researched peptides

A few concrete cases make the bands easier to picture. Semaglutide, the molecule inside the FDA-approved prescription drugs Ozempic and Wegovy, is the classic long-acting case; research-grade semaglutide sold for laboratory use is not that product and is not FDA-approved, but the underlying molecule's reported half-life of roughly five days is what makes it a once-weekly medicine in its approved form. Tirzepatide, the molecule in the FDA-approved drugs Mounjaro and Zepbound, sits in the same long-acting range for similar structural reasons. At the opposite end, BPC-157 is a synthetic peptide widely discussed in recovery circles whose human half-life is short and not well established, because the controlled human pharmacokinetic studies that would establish it have not been done. GHK-Cu, a copper-binding peptide studied for skin, behaves differently again depending on whether it is applied topically or reaches the bloodstream. You can see each molecule's reported figures on its own data sheet, such as our pages for semaglutide, tirzepatide, BPC-157 and GHK-Cu.

Half-life, steady state and why the number matters

Half-life is not just trivia; it shapes how a molecule is studied. Pharmacologists use it to reason about steady state, the point at which the amount entering the body over time balances the amount being removed, so the level stops drifting up or down. As a rule of thumb, a compound reaches steady state after roughly four to five half-lives. That means a peptide with a half-life of days takes over a week of consistent exposure before its blood level plateaus, while a peptide that disappears within minutes essentially never accumulates. This is exactly the kind of reasoning that determines how a clinical trial is designed and how long researchers wait before measuring an effect. We deliberately do not translate any of this into personal timing or usage instructions; the pharmacokinetics are here to explain the science, not to guide use. Our overview of what peptides are covers the broader biology these numbers sit inside.

Reading half-life figures honestly: the caveats

Three cautions keep a half-life chart honest. First, most published figures for research peptides are estimates or animal-derived; for a large share of the corpus, no controlled human pharmacokinetic study exists, so a confident single number should be viewed with suspicion. Second, half-life describes how long a molecule persists, not whether it does anything useful or is safe; a long half-life is not a benefit and a short one is not a flaw, they are simply chemistry. Third, degradation during storage can change the picture entirely: a peptide that has broken down on a warm shelf is no longer the molecule its half-life was measured for, which is one more reason handling and sourcing matter, as our guide on how to store peptides explains. Research-grade peptides are, in most cases, not FDA-approved and are sold labeled for laboratory research use only, and reported human data on many of them is limited.

The bottom line

Half-life is the single number that tells you how quickly a peptide is removed from the bloodstream, and it varies enormously, from minutes for a fragile natural peptide to days for a deliberately engineered long-acting one. Sorting peptides into short, medium and long-acting bands is a useful mental model, but the exact figures should be read with care, because for many research-grade peptides the human pharmacokinetics have never been formally established. Treat any chart, including this one, as an orientation rather than a precise reference, and remember that half-life speaks only to how long a molecule lasts, not to whether it works or is safe. To see how these ideas connect to specific molecules, our data sheets and the verdict on whether BPC-157 is proven or hype show the evidence picture in detail, while our comparison of tirzepatide versus semaglutide covers the long-acting, approved-medicine end of the spectrum and our look at peptides versus HGH injections puts the growth-hormone group in context.